Suh Jin Yoon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Suh Jin Yoon has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Donglan Piao
Graduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University, Seoul 03760, Republic of Korea
1 shared publication - Eun Kyoung Seo
College of Pharmacy, Ewha Womans University, Seoul 03760, Republic of Korea
1 shared publication - Eun Sook Hwang
College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Republic of Korea
1 shared publication - Hyun Ji Lee
College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, 03760 Seoul, Republic of Korea
1 shared publication - Isoo Youn
Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612, USA
1 shared publication - Jihae Lim
College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, 03760 Seoul, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 27 April 2026
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (4) , 52067
Context-Dependent Modulation of Macrophage Plasticity by Cordycepin Drives Tumor Regression in Melanoma
Background and Aim: Cordycepin (CDC), an adenosine (ADO) analog from Cordyceps mushrooms, exhibits potent anti-tumor and immunomodulatory activities. However, the precise mechanisms governing its effects on macrophage plasticity remain poorly understood. This study aimed to isolate CDC from a high-yielding Cordyceps cultivar, validate its systemic anti-tumor efficacy, and elucidate the mechanobiological cues regulating CDC-driven macrophage functions under varying cell-density states. Experimental Procedure: CDC (>98% purity) was isolated and structurally characterized via nuclear magnetic resonance (NMR) and high-resolution electrospray ionization mass spectrometry (HR-ESI-MS). Primary bone marrow-derived macrophages and RAW264.7 cells, cultured under sparse (~30%) or confluent (100%) conditions, were treated with CDC or ADO. We evaluated cell viability, pro-inflammatory cytokine expression, and Nuclear Factor kappa B (NF-κB) p65 signaling, phagocytosis, and migration. The therapeutic potential of CDC-primed macrophages was assessed via in vitro melanoma co-culture and in vivo intratumoral adoptive transfer in B16F10 tumor-bearing mice. Key Results: Systemic administration of CDC significantly inhibited melanoma growth in vivo, promoting apoptosis, enhancing macrophage infiltration. We discovered that CDC regulates macrophage functions via a density-dependent “switch”: while CDC induced cytotoxicity in sparse cultures, it significantly augmented M1-like cytokine production in confluent states without compromising viability. This density-dependent activation was mediated by the A2A adenosine receptor (A2AR), triggering the Akt–NF-κB p65 signaling axis. Furthermore, CDC upregulated migration- and phagocytosis-associated genes, enhancing tumor cell clearance. Notably, intratumoral injection of CDC-primed macrophages markedly reduced tumor volume and size in vivo. Conclusions and Implications: CDC modulates macrophage activation through a unique mechanobiological switch. Under high-density conditions—mimicking the dense tumor microenvironment—CDC enhances A2AR-mediated NF-κB activation, boosting macrophage activation, recruitment, and phagocytosis to facilitate tumor regression. These findings establish CDC as a context-dependent immunomodulator capable of reprogramming macrophages toward a tumoricidal phenotype.
- 27 April 2026
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (4) , 52067
Open AccessContext-Dependent Modulation of Macrophage Plasticity by Cordycepin Drives Tumor Regression in Melanoma
Background and Aim: Cordycepin (CDC), an adenosine (ADO) analog from Cordyceps mushrooms, exhibits potent anti-tumor and immunomodulatory activities. However, the precise mechanisms governing its effects on macrophage plasticity remain poorly understood. This study aimed to isolate CDC from a high-yielding Cordyceps cultivar, validate its systemic anti-tumor efficacy, and elucidate the mechanobiological cues regulating CDC-driven macrophage functions under varying cell-density states. Experimental Procedure: CDC (>98% purity) was isolated and structurally characterized via nuclear magnetic resonance (NMR) and high-resolution electrospray ionization mass spectrometry (HR-ESI-MS). Primary bone marrow-derived macrophages and RAW264.7 cells, cultured under sparse (~30%) or confluent (100%) conditions, were treated with CDC or ADO. We evaluated cell viability, pro-inflammatory cytokine expression, and Nuclear Factor kappa B (NF-κB) p65 signaling, phagocytosis, and migration. The therapeutic potential of CDC-primed macrophages was assessed via in vitro melanoma co-culture and in vivo intratumoral adoptive transfer in B16F10 tumor-bearing mice. Key Results: Systemic administration of CDC significantly inhibited melanoma growth in vivo, promoting apoptosis, enhancing macrophage infiltration. We discovered that CDC regulates macrophage functions via a density-dependent “switch”: while CDC induced cytotoxicity in sparse cultures, it significantly augmented M1-like cytokine production in confluent states without compromising viability. This density-dependent activation was mediated by the A2A adenosine receptor (A2AR), triggering the Akt–NF-κB p65 signaling axis. Furthermore, CDC upregulated migration- and phagocytosis-associated genes, enhancing tumor cell clearance. Notably, intratumoral injection of CDC-primed macrophages markedly reduced tumor volume and size in vivo. Conclusions and Implications: CDC modulates macrophage activation through a unique mechanobiological switch. Under high-density conditions—mimicking the dense tumor microenvironment—CDC enhances A2AR-mediated NF-κB activation, boosting macrophage activation, recruitment, and phagocytosis to facilitate tumor regression. These findings establish CDC as a context-dependent immunomodulator capable of reprogramming macrophages toward a tumoricidal phenotype.